RBC Capital Comments on Biogen (BIIB) and Tecfidera PML Case; Analyst Maintains Outperform Rating
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/13/2026
- Wall Street ends higher as SpaceX's market debut dominates
- SpaceX prices historic IPO at $135/share in largest ever new listing
- 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
- UBS cuts gold price forecasts on delayed Fed easing outlook
- Brent falls to lowest since March on expected peace deal
- NASDAQ adds five companies to NASDAQ-100 index in quarterly rebalance
- Super Micro Computer establishes $1.25 billion stock sale agreement
- Wall Street ends higher as SpaceX's market debut dominates
- 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
- SpaceX Shares Indicated To Open At $155
Baird Upgrades Biogen (BIIB) to Outperform
October 22, 2014 12:45 PM EDTBaird upgraded Biogen (NASDAQ: BIIB) from Neutral to Outperform with a price target of $382.00.
For an analyst ratings summary and ratings history on Biogen click here. For more ratings news on Biogen click here.
Shares of Biogen closed at $326.77 yesterday.
... MoreBiogen Idec (BIIB) Says Tecfidera Patient Who Died had Low White Blood Cell Counts
October 22, 2014 11:52 AM EDTBiogen Idec Inc. (BIIB) is seeing some unnecessary weakness Wednesday following Q3 results and the company's conference call.
Earlier, the WSJ cited the company as saying it confirmed a... More
Biogen (BIIB): Deutsche Bank Comments on Recent Weakness And Compares it to Celgene (CELG)
October 22, 2014 10:52 AM EDTDeutsche Bank maintained a Buy rating on Biogen (NASDAQ: BIIB) with a price target of $430. Analyst Robyn Karnauskas commented on recent weakness and compared the stock to Celgene (NASDAQ: CELG). Overall, she is positive on both stocks.
"Biogen is trading weak post earnings due to 1) slower sequential revenue growth and 2) One PML case with Tecfidera disclosed on todays call. While we note that there is a good risk/reward... More
Biogen Idec (BIIB) Tops Q3 EPS by 31c; Boosts FY14 EPS Outlook
October 22, 2014 7:06 AM EDTBiogen Idec (NASDAQ: BIIB) reported Q3 EPS of $3.80, $0.31 better than the analyst estimate of $3.49. Revenue for the quarter came in at $2.5 billion versus the consensus estimate of $2.48 billion.
The third quarter was a period of significant achievement as we continued to make progress against our... More
